167 related articles for article (PubMed ID: 31755385)
1. Plasminogen Receptors in Human Malignancies: Effects on Prognosis and Feasibility as Targets for Drug Development.
Gonias SL; Zampieri C
Curr Drug Targets; 2020; 21(7):647-656. PubMed ID: 31755385
[TBL] [Abstract][Full Text] [Related]
2. Fibrinolysis protease receptors promote activation of astrocytes to express pro-inflammatory cytokines.
Pontecorvi P; Banki MA; Zampieri C; Zalfa C; Azmoon P; Kounnas MZ; Marchese C; Gonias SL; Mantuano E
J Neuroinflammation; 2019 Dec; 16(1):257. PubMed ID: 31810478
[TBL] [Abstract][Full Text] [Related]
3. Plasmin generation dependent on alpha-enolase-type plasminogen receptor is required for myogenesis.
López-Alemany R; Suelves M; Muñoz-Cánoves P
Thromb Haemost; 2003 Oct; 90(4):724-33. PubMed ID: 14515195
[TBL] [Abstract][Full Text] [Related]
4. S100A10, annexin A2, and annexin a2 heterotetramer as candidate plasminogen receptors.
Kwon M; MacLeod TJ; Zhang Y; Waisman DM
Front Biosci; 2005 Jan; 10():300-25. PubMed ID: 15574370
[TBL] [Abstract][Full Text] [Related]
5. Alpha-enolase plasminogen receptor in myogenesis.
Lopez-Alemany R; Suelves M; Diaz-Ramos A; Vidal B; Munoz-Canoves P
Front Biosci; 2005 Jan; 10():30-6. PubMed ID: 15574344
[TBL] [Abstract][Full Text] [Related]
6. The fibrinolytic system: A new target for treatment of depression with psychedelics.
Idell RD; Florova G; Komissarov AA; Shetty S; Girard RB; Idell S
Med Hypotheses; 2017 Mar; 100():46-53. PubMed ID: 28236848
[TBL] [Abstract][Full Text] [Related]
7. [The urokinase-type plasminogen activator system and its role in tumor progression].
Kugaevskaya EV; Gureeva TA; Timoshenko OS; Solovyeva NI
Biomed Khim; 2018 Nov; 64(6):472-486. PubMed ID: 30632975
[TBL] [Abstract][Full Text] [Related]
8. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy.
Sidenius N; Blasi F
Cancer Metastasis Rev; 2003; 22(2-3):205-22. PubMed ID: 12784997
[TBL] [Abstract][Full Text] [Related]
9. Urokinase-type plasminogen activator stimulation of monocyte matrix metalloproteinase-1 production is mediated by plasmin-dependent signaling through annexin A2 and inhibited by inactive plasmin.
Zhang Y; Zhou ZH; Bugge TH; Wahl LM
J Immunol; 2007 Sep; 179(5):3297-304. PubMed ID: 17709546
[TBL] [Abstract][Full Text] [Related]
10. Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis.
Schmitt M; Wilhelm O; Jänicke F; Magdolen V; Reuning U; Ohi H; Moniwa N; Kobayashi H; Weidle U; Graeff H
J Obstet Gynaecol (Tokyo 1995); 1995 Apr; 21(2):151-65. PubMed ID: 8556577
[TBL] [Abstract][Full Text] [Related]
11. Differential proteome expression associated with urokinase plasminogen activator receptor (uPAR) suppression in malignant epithelial cancer.
Saldanha RG; Xu N; Molloy MP; Veal DA; Baker MS
J Proteome Res; 2008 Nov; 7(11):4792-806. PubMed ID: 18808175
[TBL] [Abstract][Full Text] [Related]
12. Fibrinolysis: the key to new pathogenetic mechanisms.
Zorio E; Gilabert-Estellés J; España F; Ramón LA; Cosín R; Estellés A
Curr Med Chem; 2008; 15(9):923-9. PubMed ID: 18473800
[TBL] [Abstract][Full Text] [Related]
13. Tranexamic acid mediates proinflammatory and anti-inflammatory signaling via complement C5a regulation in a plasminogen activator-dependent manner.
Barrett CD; Moore HB; Kong YW; Chapman MP; Sriram G; Lim D; Moore EE; Yaffe MB
J Trauma Acute Care Surg; 2019 Jan; 86(1):101-107. PubMed ID: 30575685
[TBL] [Abstract][Full Text] [Related]
14. The urokinase-type plasminogen activator and the generation of inhibitors of urokinase activity and signaling.
Carriero MV; Stoppelli MP
Curr Pharm Des; 2011; 17(19):1944-61. PubMed ID: 21711235
[TBL] [Abstract][Full Text] [Related]
15. Urokinase-type plasminogen activator supports liver repair independent of its cellular receptor.
Shanmukhappa K; Sabla GE; Degen JL; Bezerra JA
BMC Gastroenterol; 2006 Nov; 6():40. PubMed ID: 17134505
[TBL] [Abstract][Full Text] [Related]
16. Functions of the plasminogen receptor Plg-R
Miles LA; Vago JP; Sousa LP; Parmer RJ
J Thromb Haemost; 2020 Oct; 18(10):2468-2481. PubMed ID: 32662180
[TBL] [Abstract][Full Text] [Related]
17. The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target.
Sharma MC; Sharma M
Curr Pharm Des; 2007; 13(35):3568-75. PubMed ID: 18220793
[TBL] [Abstract][Full Text] [Related]
18. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator.
Bugge TH; Flick MJ; Danton MJ; Daugherty CC; Romer J; Dano K; Carmeliet P; Collen D; Degen JL
Proc Natl Acad Sci U S A; 1996 Jun; 93(12):5899-904. PubMed ID: 8650190
[TBL] [Abstract][Full Text] [Related]
19. High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma.
Ulisse S; Baldini E; Sorrenti S; Barollo S; Gnessi L; Catania A; Pellizzo MR; Nardi F; Mian C; De Antoni E; D'Armiento M; Frati L
J Clin Endocrinol Metab; 2011 Feb; 96(2):504-8. PubMed ID: 21106716
[TBL] [Abstract][Full Text] [Related]
20. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
